{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiabovkbgbq6ds7q5p7xhyqxuyf5ap7q3o3pohqc7x5swrb35zvcdq",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mn5r733skq72"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidnt52hen23rxuo33oeg3rkq2bq54h2l7j4p35vudptuh7v45zgpm"
    },
    "mimeType": "image/jpeg",
    "size": 86136
  },
  "path": "/news/2026-05-cell-engager-advanced-solid-tumors.html",
  "publishedAt": "2026-05-31T10:00:02.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a so-called bispecific T-cell engager (TCER) that specifically links cancer cells with T cells, thereby directly activating the immune system to fight the tumor. To achieve this, the molecule simultaneously binds to two targets: a protein produced in tumor cells known as the tumor antigen MAGEA4/8, and a molecule on the surface of the body's immune cells (CD3). These immune cells, known as T lymphocytes, are thereby directed specifically to the tumor locations and activated so that they can destroy the cancer cells.",
  "title": "New T-cell engager shows promise for advanced solid tumors"
}